Keyword: Takeda

Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market.

Sanofi's beleaguered dengue vaccine is expected to win European approval in December following a committee's vote in favor of the shot this week.

Shire’s $1 billion plasma fractionation plant in Georgia has gone through three owners but is now officially open.

Cancer drugmakers cut prices by 56.7% for China; Celltrion's Rituxan biosim wins FDA panel support; Otsuka renews digital pill deal with Proteus.

Several big drugmakers have posted big share price gains in the first nine months of the year, while other companies have seen only modest declines.

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

Tasuku Honjo wins Nobel Prize for PD-1 research; Legend fires back at CAR-T data fabrication allegation; Takeda alumni demand more on Shire buyout.

Roche’s Hemlibra officially has the hemophilia indication it’s been waiting for—and that its competitors have been dreading.

It’s no secret that Takeda’s pending Shire megadeal has its critics, and some of them are now demanding behind-the-scenes info to justify the buy.

The FDA is updating its citizen petition review policy to consider whether branded companies are filing the requests to delay generics competition.